A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

A Phase 1 Double Blind, Randomized Clinical Study to Evaluate the Safety of Human Milk Oligosaccharides Following Antibiotic Therapy in Subjects With C. Difficile-associated Diarrhea

NCT03793686•Prolacta Bioscience

View on ClinicalTrials.gov

Summary

This Phase I double blind, randomized clinical study to evaluate the safety of human milk oligosaccharides (HMO) is designed to assess the safety and dosage ranging of PBCLN-003 in adults with Clostridium difficile-associated diarrhea (CDAD). Within 3 dose cohort, subjects will be randomized in a 3:1 ratio to receive PBCLN-003 or placebo.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Enrollment episode of CDAD diagnosed based on \> 3 loose stools per day and detection of CD toxin by nucleic acid amplification tests (NAAT), EIA or GDH
•Mild to moderate CDAD during enrollment episode (per Society of Hospital Epidemiologists of America (SHEA)/lnfectious Disease Society of America(ISDA) criteria)
•Current therapy with standard of care antibiotics for recurrent CDAD(vancomycin, metronidazole, fidaxomicin)
•BMI \> 18.5 and \< 40
•Age 18 years or older
•Agreement to adhere to the study protocol
•Informed consent is obtained
•Women who are capable of bearing children must have a negative pregnancy test at the time of screening
•Female subjects of childbearing potential must use birth control (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) during the study period and for up to 8 weeks after the first drug of study.

Exclusion Criteria

•Severe CDAD during enrollment episode (per SHEA/ISDA criteria) characterized as follows:
•* History of five (5) or more recurrences of CDAD within the past 12 months prior to potential study enrollment
•* History of fecal microbiome transplant or other microbiome directed experimental intervention for CDAD
•* History (ever) of CD complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD
•Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
•Initiating a new diet or weight loss amounting to 10% within two weeks prior to date of study entry
•Enrolled in another clinical study for the therapy of CDAD or affecting nutritional management during the study period
•Enrolled or has been enrolled in another experimental (IND) study within two weeks prior to date of study entry
•Is pregnant or lactating
•History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids
+5 more criteria

Locations (1)

Infectious Disease Specialist

Idaho Falls, Idaho, United States

Key Dates

Start Date

December 6, 2018

Primary Completion Date

September 1, 2020

Completion Date

September 1, 2020

Last Updated

October 19, 2020

Enrollment

ACTUAL participants

Conditions

Clostridium Difficile Diarrhea

Interventions

PBCLN-003

DRUG

Placebo

DRUG

Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea

NCT06839209

Clostridium; Difficile, As Cause of Disease Classified ElsewhereClostridium Difficile Diarrhea

View study

TERMINATEDPHASE4

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

NCT02200328

Clostridium Difficile Diarrhea

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions